Navigation Links
LSTM to lead $30 million research program into malaria in pregnancy
Date:3/7/2008

The Liverpool School of Tropical Medicine has received a $30 million grant from the Bill & Melinda Gates Foundation to improve the control and treatment of malaria in pregnancy in Africa, Asia and Latin America. The five year programme will directly benefit the 50 million women who face exposure to malaria whilst pregnant every year.

The grant will fund research at Liverpool and at 38 partner institutions in 27 countries around the world. The research consortium is also supported by the European Union, and is seeking additional funding from other donors.

Malaria in pregnancy is a major cause of severe maternal anaemia and preventable low birth weight in infants, which greatly increases risk of death. It is estimated that more effective control of malaria in pregnancy could save the lives of up to 100,000 children every year in Africa alone.

There is less detailed information on the effects of malaria in pregnancy outside Africa. Although transmission rates are lower, natural immunity is also lower, therefore the consequences of malaria infection are more often severe, with a much higher risk of the death of the mother, baby or both.

The primary aims of the research address four key areas:

Burden

  • Obtain a better understanding of the burden of malaria in pregnancy in regions outside Africa where malaria is common.

Treatment

  • Further evaluate which of the new generation of antimalarial drugs can be used safely and effectively for the treatment of pregnant women with malaria in Africa, Asia and Latin America.

Prevention

  • Identify safe alternative antimalarials for the prevention of malaria in pregnancy in Africa to replace the commonly used drug sulphadoxine-pyrimethamine (to which many malaria parasites have developed resistance).

  • Determine the most effective combinations of drugs and other tools that reduce the risk of mosquito bites (eg insecticide treated bednets), thus preventing malaria in pregnancy.

  • Evaluate new interventions for the control of malaria in pregnancy in low transmission regions outside of Africa.

Coverage and utilisation

  • Establish the best way to increase the coverage and utilisation of existing strategies to control malaria in pregnancy.

Consortium leader Dr Feiko ter Kuile explained: In contrast to the recent focus on preventing malaria deaths in young children, the impact of malaria in pregnancy has until now been a relatively neglected area of research. This grant provides researchers from all over the world with the opportunity to conduct a much expanded and much needed research programme that is focussed on this other high risk group.

There are four main research theme areas consisting of ten major projects. The work is conducted jointly by expert institutions from all over the world that have agreed to use standardized methods and share information. This consortium approach generates a new momentum of life-saving research, which will provide evidence-based policy changes in the shortest possible time.

Defeating malaria will require new and better tools to prevent and treat the disease in pregnancy, said Dr Regina Rabinovich, director of Infectious Diseases Development at the Gates Foundation. By undertaking this important research, Liverpool and its partners will help bring the world closer to the ultimate goal of malaria eradication.


'/>"/>

Contact: Alan Hughes
a.p.hughes@liv.ac.uk
44-151-705-3308
Liverpool School of Tropical Medicine
Source:Eurekalert

Related medicine news :

1. Alleged Multi-Million Dollar Fraud Ring Target of Federal Lawsuit
2. Whole Planet Foundation(TM) (a Whole Foods Market Foundation) and Nobel Peace Prize Winner Dr. Muhammad Yunus Partner With Natural Foods Vendors, Pledging Over $1 Million to Help Combat Poverty
3. New Jersey Healthcare Consulting Firm to Pay U.S. $2.875 Million to Resolve Allegations of Medicare Fraud
4. Trevena, Inc. Announces $24 Million Series A Financing
5. Cathedral Healthcare System to Pay U.S. $5.3 Million to Resolve Allegations Involving Inflated Charges to Obtain Higher Medicare Reimbursement
6. LeMaitre Vascular Reports Q4 2007 Revenue of $11.1 Million, a 27% Increase
7. Robert H. Smith Feeding the Future with $15 Million Gift to Hebrew University of Jerusalem
8. Kidney Patient Advocacy Community Joins National Effort to Raise Awareness about Health Crisis Impacting more than 26 Million Americans
9. Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million
10. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
11. Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology: